loading...| Preferred Name |
Irinotecan Hydrochloride |
|
| Synonyms |
|
|
| Definitions |
The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. |
|
| ID |
http://purl.obolibrary.org/obo/NCIT_C1381 |
|
| Accepted_Therapeutic_Use_For |
State IVB Cervical cancer; Colorectal cancer; Esophageal cancer; Gastric cancer; Non-small cell lung cancer; Small cell lung cancer |
|
| ALT_DEFINITION |
A drug used alone or with other drugs to treat colon cancer or rectal cancer that has spread to other parts of the body or has come back after treatment with fluorouracil. It is also being studied in the treatment of other types of cancer. Camptosar blocks certain enzymes needed for cell division and DNA repair, and it may kill cancer cells. It is a type of topoisomerase inhibitor and a type of camptothecin analog. |
|
| CAS_Registry |
136572-09-3 |
|
| Chemical_Formula |
C33H38N4O6.HCl.3H2O |
|
| code |
C1381 |
|
| Contributing_Source |
CTRP FDA |
|
| definition |
The hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent. |
|
| Display_Name |
Irinotecan Hydrochloride |
|
| FDA_UNII_Code |
042LAQ1IIS |
|
| Has_Free_Acid_Or_Base_Form | ||
| Has_Target | ||
| in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 |
|
| Is_Value_For_GDC_Property | ||
| label |
Irinotecan Hydrochloride |
|
| Legacy Concept Name |
Irinotecan |
|
| Maps_To |
Irinotecan Hydrochloride |
|
| NCI_Drug_Dictionary_ID |
41714 |
|
| PDQ_Closed_Trial_Search_ID |
41714 |
|
| PDQ_Open_Trial_Search_ID |
41714 |
|
| Preferred_Name |
Irinotecan Hydrochloride |
|
| prefixIRI |
NCIT:C1381 |
|
| prefLabel |
Irinotecan Hydrochloride |
|
| Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
| UMLS_CUI |
C0594375 |
|
| subClassOf |